News | News By Subject | News by Disease News By Date | Search News

Lymphoma News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
3 Cancer Biotechs to Watch at ASCO     5/9/2017
Novartis AG (NVS) Remains Hush-Hush About CAR-T Trial But the FDA is Impressed and Thinks It's a Breakthrough     4/20/2017
FDA Calls It! Seattle Genetics (SGEN)' Adcetris is a Breakthrough for Lymphoma     11/14/2016
Takeda (TKPYY), Seattle Genetics (SGEN) Show Off Significant Phase III ALCANZA Data for T-Cell Lymphoma     8/1/2016
Celgene (CELG)'s Revlimid Fails to Extend Survival in Lymphoma Study     7/26/2016
Genentech (RHHBY) Receives a Blow After Lymphoma Drug Flunks Phase III Test     7/19/2016
Genentech (RHHBY)’s Gazyva Meets Primary Endpoint Early in Late-Stage Study     5/27/2016
FDA Lifts Partial Clinical Hold on Medivation (MDVN)'s Pidilizumab     3/9/2016
FDA Green Lights Genentech (RHHBY)'s Gazyva for Patients with Previously Treated Follicular Lymphoma     2/26/2016
Orphan Drug Designation Status for Acerta Pharma Drug Vindicates AstraZeneca PLC (AZN)’s $4 Billion Deal     2/26/2016
Analyst Questions High Cost of T Cell Therapies as Potential Frontline Treatment for Blood Cancers     2/25/2016
Medivation (MDVN) Stock Falls After the FDA Places Partial Clinical Hold on MDV9300     1/27/2016
Novartis AG (NVS) Takes Another 2.5% Stake in Gamida Cell     10/12/2015
EXCLUSIVE: Pediatric Patients Could Benefit Most From New Oncoceutics Cancer Drug, Says Exec     7/2/2015
ASCO15 EXCLUSIVE: Genentech (RHHBY) VP Tells BioSpace (DHX) Gazyva a "Clear Advance" For NHL Treatment     6/1/2015

News from Around the Web
Why It Feels So Good To Scratch An Itch, Published In Proceedings Of The Entomological Society Of Washington     2/29/2016
Kite Pharma (KITE)'s CEO On Cancer-Killing T-Cells: "This Is A Revolution"     2/29/2016
BioSpace’s Favorite FDA Tricks Or Treats     10/24/2014
Novel Drug Shuts Down Master Protein Key to Lymphoma, Weill Cornell Medical College Study     8/5/2013
New Technique Catalogs Lymphoma-Linked Genetic Variations, Johns Hopkins University School of Medicine Study     12/27/2012
B-Cell Lymphoma: New Research Provides Breakthrough in Understanding Common Cancer, University of Sheffield Study     6/10/2011
"Sniffing Out" Lymphoma Genes by Turning Dogs into Humans, North Carolina State University Study     4/7/2011
Gene Mutation Linked to Deadly Lymphoma, University of Rochester Study     1/3/2011
National Institutes of Health (NIH) Scientists Identify Possible Gene Target for Treating a Form of Lymphoma     12/29/2010
Conjugate Drug Shows Benefit in Lymphoma, University of Texas Study     11/4/2010
Hepatitis B Linked To Lymphoma In National Cancer Institute and Sun Ha Jee of Yonsei University Study     8/4/2010
Vitamin K May Protect Against Developing Non-Hodgkin's Lymphoma, Say Mayo Clinic Researchers     4/21/2010
Seaweed Extract May Hold Promise for Non-Hodgkin's Lymphoma Treatment, The Hashemite University Study     3/11/2010
Approved Lymphoma Drug Shows Promise In Early Tests Against Bone Cancer, University of Rochester Medical Center Study     11/6/2009
Genentech, Inc. (DNA) And Biogen Idec, Inc. (California) (BIIB)'s Rituximab Maintenance Therapy Improves Survival In Patients With Relapsed Follicular Lymphoma, Rabin Medical Center (Beilinson Hospital) Study     2/11/2009

Press Releases
miRagen Receives EU Orphan Medicinal Product Designation For MRG-106 For The Treatment Of Cutaneous T-Cell Lymphoma     5/24/2017
FDA Grants Bayer (BAY) Priority Review For Investigational Compound Copanlisib In Follicular Lymphoma     5/17/2017
Clinigen And Onxeo Initiate Managed Access Programme For Belinostat In Europe For Patients With Peripheral T-Cell Lymphoma (PTCL)     5/11/2017
Merck & Co. (MRK) Release: European Commission (EC) Approves KEYTRUDA (Pembrolizumab) For Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma Who Failed Autologous Stem Cell Transplant And Brentuximab Vedotin (BV), Or Who Are Transplant-Ineligible And Have Failed BV     5/5/2017
Verastem (VSTM) Announces Long Term Follow-Up Data From The DYNAMO Study Selected For Oral Presentation At The 14th International Conference On Malignant Lymphoma     5/3/2017
Triphase Accelerator Reports Completion Of Initial Regulatory Interactions With FDA And Health Canada For TRPH-222 For The Treatment Of Lymphoma     5/1/2017
PIQUR Therapeutics AG Receives EMA Orphan Drug Designation For PQR309 In Diffuse Large B-Cell Lymphoma     4/27/2017
Epizyme (EPZM) Announces Tazemetostat Fast Track Designation For Follicular Lymphoma And Plenary Session On Phase II NHL Data At ICML     4/25/2017
Clinigen And Onxeo Initiate Managed Access Programme For Belinostat In Europe For Patients With Peripheral T-Cell Lymphoma (PTCL)     4/25/2017
Argenx Launches Phase II Study Of ARGX-110 As A Monotherapy In Relapsed/Refractory CTCL Patients     4/12/2017
ArQule (ARQL) Receives Clearance Of Investigational New Drug Application From The FDA For Proprietary Reversible BTK Inhibitor, ARQ 531     4/11/2017
Alexo Announces Initiation Of Phase I Clinical Trial Of ALX148 For The Treatment Of Advanced Solid Tumors And Lymphoma     4/10/2017
Medivir (MVRBF) Announces Positive Data From The Phase II Study Of Remetinostat In Patients With Early-Stage Cutaneous T-Cell Lymphoma     4/7/2017
Sutro Biopharma ADC Targeting CD74 Eradicates B-Cell Hematologic Malignancy, Prolongs Survival In Tumor Models     4/3/2017
Halozyme (HALO) Release: FDA Advisory Committee Provides Unanimous Recommendation For Subcutaneous Rituximab Coformulated With Halozyme Enhanze Technology     3/29/2017

//-->